Septerna (NASDAQ:SEPN) Price Target Raised to $48.00

Septerna (NASDAQ:SEPN) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $38.00 to $48.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 9.35% from the company’s previous close.

Several other analysts have also recently commented on the company. Truist Financial boosted their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Raymond James Financial restated a “strong-buy” rating and issued a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. Stifel Nicolaus set a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th. HC Wainwright upped their target price on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, JonesTrading increased their target price on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $52.44.

Septerna Price Performance

Septerna stock traded up $0.10 during midday trading on Wednesday, reaching $43.90. The company had a trading volume of 155,599 shares, compared to its average volume of 362,171. Septerna has a 12-month low of $10.74 and a 12-month high of $51.10. The company has a market capitalization of $2.05 billion, a P/E ratio of -81.21 and a beta of 2.29. The firm’s fifty day simple moving average is $36.37 and its 200-day simple moving average is $29.94.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, analysts expect that Septerna will post -1.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This trade represents a 13.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Elizabeth Bhatt sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. This trade represents a 12.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 72,828 shares of company stock worth $2,684,314. 5.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently modified their holdings of SEPN. Group One Trading LLC grew its stake in shares of Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of Septerna during the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new stake in shares of Septerna during the 3rd quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Septerna in the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Septerna in the fourth quarter worth approximately $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.